Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18927346 | COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVES | October 2024 | April 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18742375 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | June 2024 | February 2026 | Allow | 20 | 1 | 1 | No | No |
| 18680558 | KIF18A INHIBITORS | May 2024 | July 2025 | Allow | 13 | 1 | 1 | No | No |
| 18710989 | MELAMINE PROCESS WITH A TWO-STAGE PURIFICATION OF MELAMINE OFFGAS | May 2024 | June 2025 | Allow | 13 | 0 | 0 | No | No |
| 18626881 | REAGENTS FOR QUANTITATIVE MASS SPECTROMETRY | April 2024 | September 2024 | Allow | 5 | 1 | 1 | No | No |
| 18618311 | Pharmaceutical Compositions Having Improved Storage Stability | March 2024 | February 2025 | Allow | 10 | 1 | 0 | No | No |
| 18612000 | Methods and Compositions for Treatment of Inflammatory Disease | March 2024 | November 2025 | Allow | 20 | 1 | 1 | No | No |
| 18606834 | SPECIFIC AKT3 ACTIVATOR AND USES THEREOF | March 2024 | January 2026 | Allow | 22 | 2 | 1 | No | No |
| 18606165 | PHARMACEUTICAL COMPOSITION WITH PRIMARY AND SECONDARY THERAPEUTIC AGENTS | March 2024 | July 2024 | Allow | 5 | 0 | 1 | No | No |
| 18606994 | INJECTABLE GOLD-BASED PHARMACEUTICAL COMPOSITION | March 2024 | July 2024 | Allow | 5 | 0 | 1 | No | No |
| 18604731 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | March 2024 | June 2025 | Abandon | 15 | 0 | 1 | Yes | No |
| 18443509 | METALLOENZYME INHIBITOR COMPOUNDS | February 2024 | March 2025 | Allow | 13 | 1 | 1 | No | No |
| 18433881 | THERAMUTEIN MODULATORS | February 2024 | October 2024 | Allow | 8 | 0 | 0 | No | No |
| 18422704 | DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS | January 2024 | June 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18395739 | METHOD OF INHIBITING KINASE BY CAMSYLATE SALTS OF TRIAZOLOPYRAZINE DERIVATIVES | December 2023 | January 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18395738 | METHOD OF PREPARING CAMSYLATE SALTS OF TRIAZOLOPYRAZINE DERIVATIVES | December 2023 | January 2025 | Allow | 12 | 1 | 0 | No | No |
| 18528433 | SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE | December 2023 | April 2025 | Allow | 17 | 2 | 1 | No | No |
| 18566301 | Piperidine Urea Derivatives for Use as Inotropic Agents | December 2023 | March 2026 | Allow | 27 | 1 | 0 | No | No |
| 18519150 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | November 2023 | April 2025 | Allow | 16 | 1 | 1 | No | No |
| 18517596 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION | November 2023 | February 2026 | Allow | 26 | 1 | 2 | Yes | No |
| 18513888 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | November 2023 | February 2025 | Allow | 15 | 0 | 1 | No | No |
| 18510594 | 7-IMINO-5-(1H-INDOL-3-YL)-1,3-SUBSTITUTED-7,8-DIHDROPYRIMIDO[4,5-D]PYRIMIDINE-2,4(1H,3H)-DIONE AS ANTI-INFLAMMATORY AGENTS | November 2023 | July 2024 | Allow | 8 | 1 | 1 | No | No |
| 18504660 | COMPOUNDS FOR THE TREATMENT OF SARS | November 2023 | August 2025 | Allow | 21 | 2 | 1 | No | No |
| 18504778 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | November 2023 | March 2025 | Allow | 16 | 2 | 1 | Yes | No |
| 18500735 | METHOD FOR TREATING CANCER USING A BCL-2 INHIBITOR IN CONJUNCTION WITH AN ALPHA-EMITTING RADIOIMMUNOTHERAPEUTIC | November 2023 | September 2024 | Allow | 11 | 1 | 1 | No | No |
| 18496043 | NEW COMPOUNDS AND METHODS OF THEIR MANUFACTURING | October 2023 | August 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18383992 | COMBINATION THERAPY FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | October 2023 | June 2025 | Allow | 20 | 1 | 1 | No | No |
| 18383301 | PYRROLOPYRIMIDINE ITK INHIBITORS | October 2023 | January 2025 | Allow | 14 | 1 | 1 | No | No |
| 18492411 | COMPOUNDS FOR THE TREATMENT OF SARS | October 2023 | August 2025 | Allow | 22 | 2 | 1 | No | No |
| 18469860 | Compounds and Methods of Their Manufacturing | September 2023 | August 2024 | Allow | 11 | 1 | 1 | Yes | No |
| 18467185 | CHEMICAL COMPOUNDS | September 2023 | May 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18453743 | THERAPIES WITH 3RD GENERATION EGFR TYROSINE KINASE INHIBITORS | August 2023 | November 2025 | Allow | 26 | 3 | 0 | No | No |
| 18263203 | CYCLOPROPYLAMIDE COMPOUNDS AGAINST PARASITES IN FISH | July 2023 | February 2026 | Allow | 31 | 1 | 0 | No | No |
| 18226570 | POLYMORPHS OF SELINEXOR | July 2023 | March 2025 | Allow | 20 | 1 | 0 | No | No |
| 18219511 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | July 2023 | October 2024 | Allow | 15 | 0 | 1 | No | No |
| 18271084 | METHOD FOR INDUSTRIALLY PRODUCING DIALKYL CARBONATE AND DIOL | July 2023 | March 2026 | Allow | 32 | 0 | 0 | No | No |
| 18214825 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | June 2023 | February 2025 | Allow | 19 | 1 | 1 | No | No |
| 18207887 | METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES | June 2023 | January 2025 | Allow | 19 | 1 | 1 | No | No |
| 18319402 | CRYSTALLINE FORMS OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE APROCITENTAN | May 2023 | January 2025 | Allow | 20 | 1 | 1 | No | No |
| 18197361 | COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS | May 2023 | June 2025 | Abandon | 25 | 1 | 1 | Yes | No |
| 18309867 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | May 2023 | January 2025 | Allow | 20 | 2 | 1 | No | No |
| 18033994 | METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF | April 2023 | March 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18306515 | SYNTHETIC ROUTE TO SCOPOLAMINE AND/OR ATROPINE | April 2023 | January 2025 | Allow | 20 | 1 | 1 | No | No |
| 18250287 | DEUTERATED HPK1 KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | April 2023 | January 2026 | Allow | 33 | 1 | 0 | No | No |
| 18138644 | COMBINATION THERAPY INVOLVING DIARYL MACROCYCLIC COMPOUNDS | April 2023 | August 2025 | Abandon | 28 | 1 | 1 | Yes | No |
| 18033173 | ANTICANCER COMPOUNDS SELECTIVE FOR ER-POSITIVE CANCERS | April 2023 | February 2026 | Allow | 34 | 1 | 0 | No | No |
| 18301693 | QUINOXALINE COMPOUNDS AND USES THEREOF | April 2023 | January 2025 | Allow | 21 | 1 | 1 | No | No |
| 18300501 | CRYSTALLINE FORMS OF GSK1278863, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | April 2023 | January 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18300141 | CRYSTALS | April 2023 | January 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18031749 | METHODS OF CONTRACEPTION USING NOMEGESTROL ACETATE AND ESTRADIOL | April 2023 | January 2026 | Allow | 33 | 1 | 0 | No | No |
| 18299622 | PROCESS FOR PREPARING BTK INHIBITORS | April 2023 | December 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18031045 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | April 2023 | December 2025 | Allow | 32 | 0 | 1 | No | No |
| 18248393 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | April 2023 | November 2025 | Allow | 31 | 1 | 0 | No | No |
| 18128362 | METHOD FOR THE PREPARATION OF SULFINPYRAZONE | March 2023 | February 2026 | Allow | 35 | 0 | 0 | No | No |
| 18125826 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | March 2023 | January 2025 | Allow | 21 | 1 | 1 | No | No |
| 18123812 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | March 2023 | March 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18121886 | THIENOPYRIMIDINE DERIVATIVES AND PRODUCTION METHODS THEREOF | March 2023 | August 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 18120697 | Compositions Containing Dialkyl Amino Acid Ester Salts | March 2023 | March 2026 | Abandon | 36 | 0 | 1 | No | No |
| 18118549 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | March 2023 | January 2025 | Abandon | 22 | 0 | 1 | No | No |
| 18175272 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | February 2023 | February 2025 | Abandon | 24 | 0 | 1 | No | No |
| 18042057 | METHODS OF CONTROLLING OR PREVENTING INFESTATION OF PLANTS BY PLANT-PARASITIC NEMATODES OF THE GENUS APHELENCHOIDES SPP., ESPECIALLY APHELENCHOIDES BESSEYI | February 2023 | January 2026 | Allow | 35 | 1 | 0 | No | No |
| 18042069 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | February 2023 | December 2025 | Allow | 34 | 1 | 1 | No | No |
| 18168950 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | February 2023 | July 2025 | Allow | 29 | 3 | 1 | No | No |
| 18163631 | USE OF TAPINAROF FOR THE TREATMENT OF ATOPIC DERMATITIS | February 2023 | November 2025 | Allow | 33 | 1 | 1 | No | No |
| 18163151 | SALT FORMS AND POLYMORPHS OF (R)-1-(4-(6-(2-(4-(3,3-DIFLUOROCYCLOBUTOXY)-6-METHYLPYRIDIN-2-YL)ACETAMIDO) PYRIDAZIN-3-YL)-2-FLUOROBUTYL)-N-METHYL-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE | February 2023 | November 2024 | Allow | 21 | 1 | 0 | No | No |
| 18159494 | DOSAGE REGIME AND METHOD FOR TREATING PULMONARY ARTERIAL HYPERTENSION | January 2023 | January 2025 | Abandon | 24 | 0 | 1 | No | No |
| 18099611 | NOVEL BARBITURIC ACID DERIVATIVES, THEIR PREPARATION AND USE THEREOF AS LEUKOCYTE TRANSMIGRATION INHIBITORS AND FOR TREATING INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES AND CANCER | January 2023 | November 2024 | Allow | 22 | 2 | 1 | No | No |
| 18017201 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS FROM CARBOXAMIDE AND CARBOXAMIDE DERIVATIVES WITH HALOALKANOLS | January 2023 | June 2025 | Allow | 29 | 0 | 1 | No | No |
| 18016181 | VETERINARY COMPOSITIONS FOR THE TREATMENT AND/OR PREVENTION OF PROTOZOAN DISEASES AND METHODS OF PREPARATION THEREOF | January 2023 | February 2026 | Abandon | 37 | 0 | 1 | Yes | No |
| 18089641 | BIOMARKERS FOR VITILIGO | December 2022 | October 2025 | Allow | 34 | 1 | 1 | No | No |
| 18146294 | COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOF | December 2022 | August 2024 | Allow | 19 | 1 | 1 | No | No |
| 18068788 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | December 2022 | October 2024 | Allow | 22 | 2 | 0 | No | No |
| 18011836 | SANITIZING COMPOSITIONS CONTAINING IONIC LIQUID | December 2022 | February 2026 | Allow | 38 | 1 | 1 | No | No |
| 18081558 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR | December 2022 | December 2024 | Abandon | 24 | 2 | 0 | Yes | No |
| 18001352 | N-LINKED MACROCYCLIC 7-(PYRAZOL-5-YL)-INDOLE DERIVATIVES AS INHIBIORS OF MCL-1 | December 2022 | July 2025 | Abandon | 31 | 0 | 1 | No | No |
| 18077315 | TOPICAL TREATMENT OF VITILIGO BY A JAK INHIBITOR | December 2022 | January 2025 | Allow | 25 | 1 | 0 | No | No |
| 17928486 | METHOD FOR PRODUCING THIOL COMPOUND | November 2022 | January 2026 | Allow | 38 | 1 | 1 | No | No |
| 17991792 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | November 2022 | July 2025 | Allow | 32 | 2 | 2 | Yes | No |
| 17991282 | IMIDAZOLIUM REAGENT FOR MASS SPECTROMETRY | November 2022 | December 2025 | Allow | 47 | 0 | 1 | No | No |
| 17926407 | METHODS OF SYNTHESIZING FARNESYL DIBENZODIAZEPINONES | November 2022 | January 2026 | Allow | 38 | 0 | 1 | No | No |
| 17925358 | ANILINE COMPOUND USED AS RORy REGULATOR | November 2022 | November 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 18055017 | TREATMENT FOR OBESITY | November 2022 | September 2024 | Allow | 22 | 1 | 1 | No | No |
| 17986350 | TREATMENT OF THE GASTROINTESTINAL TRACT WITH DIMERIC NAPHTHALIMIDE COMPOUNDS | November 2022 | January 2025 | Allow | 26 | 1 | 1 | No | No |
| 17983097 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | November 2022 | November 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17980291 | HISTONE DEMETHYLASE INHIBITORS | November 2022 | August 2024 | Allow | 22 | 1 | 1 | No | No |
| 18051216 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | October 2022 | August 2024 | Allow | 21 | 1 | 1 | No | No |
| 17997437 | IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 | October 2022 | July 2025 | Allow | 33 | 0 | 1 | No | No |
| 17921579 | METHODS OF TREATING AGITATION ASSOCIATED WITH ALZHEIMER'S DISEASE | October 2022 | March 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17920327 | PROCESS FOR THE ACYLATION OF AN ALPHA, OMEGA-ALKANDIOL | October 2022 | September 2025 | Allow | 35 | 1 | 0 | No | No |
| 17919932 | PROCESS FOR NITRATE ESTER FORMATION OF AN ALPHA,OMEGA-ALKANEDIOL MONOACYLATE | October 2022 | December 2025 | Allow | 38 | 2 | 0 | No | No |
| 17996499 | MEDICAL USE OF DARIDOREXANT | October 2022 | December 2025 | Allow | 38 | 1 | 0 | No | No |
| 18046848 | METHODS AND COMPOSITIONS FOR TREATING SUBJECTS WITH METABOLIC DISORDERS AND CORONAVIRUS INFECTIONS | October 2022 | December 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17963036 | DIHYDROPYRIDINES FOR THE TREATMENT OF COGNITIVE IMPAIRMENT OR TRAUMATIC BRAIN INJURY | October 2022 | October 2024 | Allow | 24 | 1 | 1 | No | No |
| 17917683 | SUSTAINED-RELEASE BASE | October 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17959750 | 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | October 2022 | January 2025 | Abandon | 27 | 1 | 1 | No | No |
| 17957549 | Novel barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer | September 2022 | November 2024 | Allow | 25 | 2 | 1 | No | No |
| 17957932 | TREATMENT OF 22Q11.2 DELETION SYNDROME WITH CANNABIDIOL | September 2022 | August 2024 | Allow | 23 | 1 | 0 | No | No |
| 17936555 | SALT FORM OF A HUMAN HISTONE METHYLTRANSFERASE EZH2 INHIBITOR | September 2022 | November 2024 | Allow | 25 | 1 | 0 | No | No |
| 17915392 | SERUM METABOLITES AS BIOMARKERS FOR CARNITINE TREATMENT OF SEPSIS | September 2022 | September 2025 | Allow | 36 | 1 | 0 | No | No |
| 17914559 | LOW-MIGRATION HINDERED PHENOL ANTIOXIDANT COMPOUND, PREPARATION METHOD AND COMPOSITION | September 2022 | January 2026 | Allow | 40 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WARD, PAUL V.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 44.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner WARD, PAUL V works in Art Unit 1622 and has examined 523 patent applications in our dataset. With an allowance rate of 96.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner WARD, PAUL V's allowance rate of 96.7% places them in the 87% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by WARD, PAUL V receive 1.34 office actions before reaching final disposition. This places the examiner in the 19% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by WARD, PAUL V is 33 months. This places the examiner in the 45% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a -0.2% benefit to allowance rate for applications examined by WARD, PAUL V. This interview benefit is in the 12% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 47.9% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 82.2% of cases where such amendments are filed. This entry rate is in the 96% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 71.9% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 13.0% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 31.2% of allowed cases (in the 96% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.